Form 4: Edgewise Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
John R Moore, General Counsel of Edgewise Therapeutics, Inc., sold 5,016 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 5,781 Common Stock on August 12, 2026; holds 15,995 after (Direct).
- Option exercise/conversion: acquired 6,718 Common Stock on August 12, 2026; holds 22,713 after (Direct).
- Open-market sale: disposed of 2,439 Common Stock at $43.81 ($106,848) on August 12, 2026; holds 20,274 after (Direct).
- Open-market sale: disposed of 59 Common Stock at $44.41 ($2,620) on August 12, 2026; holds 20,215 after (Direct).
- Open-market sale: disposed of 99 Common Stock at $44.50 ($4,406) on August 12, 2026; holds 20,116 after (Direct).
- Open-market sale: disposed of 2,419 Common Stock at $43.80 ($105,949) on August 12, 2026; holds 17,697 after (Direct).
- Option exercise/conversion: disposed of 5,781 Restricted Stock Units on August 12, 2026; holds 11,563 after (Direct).
- Option exercise/conversion: disposed of 6,718 Restricted Stock Units on August 12, 2026; holds 20,157 after (Direct).
- Grant/award: acquired 32,500 Restricted Stock Units on August 12, 2026; holds 32,500 after (Direct).
- Grant/award: acquired 65,000 Stock Option (Right to Buy) on August 12, 2026; holds 65,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $219,823 of stock on the open market.
Insider Transactions
John R Moore — Officer (General Counsel)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 5,781 | — | — | 15,995 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 6,718 | — | — | 22,713 |
| 2026-08-12 | Open-market sale | Common Stock | 2,439 | $44 | $106.8K | 20,274 |
| 2026-08-12 | Open-market sale | Common Stock | 59 | $44 | $2.6K | 20,215 |
| 2026-08-12 | Open-market sale | Common Stock | 99 | $45 | $4.4K | 20,116 |
| 2026-08-12 | Open-market sale | Common Stock | 2,419 | $44 | $105.9K | 17,697 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 5,781 | — | — | 11,563 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 6,718 | — | — | 20,157 |
| 2026-08-12 | Grant/award | Restricted Stock Units | 32,500 | — | — | 32,500 |
| 2026-08-12 | Grant/award | Stock Option (Right to Buy) | 65,000 | — | — | 65,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (5,781 shares) |
| 2026-08-12 | Option exercise/conversion (6,718 shares) |
| 2026-08-12 | Open-market sale (2,439 shares) |
| 2026-08-12 | Open-market sale (59 shares) |
| 2026-08-12 | Open-market sale (99 shares) |
| 2026-08-12 | Open-market sale (2,419 shares) |
| 2026-08-12 | Option exercise/conversion (5,781 shares) |
| 2026-08-12 | Option exercise/conversion (6,718 shares) |
| 2026-08-12 | Grant/award (32,500 shares) |
| 2026-08-12 | Grant/award (65,000 shares) |
Keywords
insider transaction, Form 4, EWTX, Edgewise Therapeutics, Inc., bearish, John R Moore
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.